Agilent Technologies has launched its 708-DS Dissolution Apparatus, a quality control instrument that can be set up for manual or automated applications to measure the release rate of an API over time.
Syringe maker Unilife attributed increased first-quarter losses to higher expenditure, costs associated with relocation to the US and the construction of its new global headquarters and production facility in York, Pennsylvania.
Outsourcing-Pharma reviews the latest financial reports from the eClinical sector with news from Datatrak International, Medidata Solutions and Perceptive Informatics.
Combatting counterfeit drugs through forging stronger partnerships is beyond profit, it is about saving lives, AstraZeneca principal scientist Dr Michael Claybourn told a workshop on global drug quality at the AAPS annual meeting in New Orleans.
IMS Health predicts China will become the world’s second largest pharmaceutical market by 2015 due to robust economic growth and healthcare reforms that allow for increased spending on drugs.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at Premier Research, Porsolt and BioStorage.
Clinical Research Advantage (CRA) is introducing its services to the Las Vegas market by opening eight new offices in the region to help trial sponsors bring drugs to market quicker and more effectively.
The USP is building a database of counterfeit essential medicines to support international drug procurement organisations, such as WHO, and the timely sharing of information between national regulators.
An academic clinical research centre that claims CROs markedly increase costs and reduce trial monitoring to box ticking, statements disputed by ACRO, has described its adoption of an in-house system.
Crucell and Eden Biodesign have entered into an agreement that sees Eden become a provider of services of contract manufacturing services for Crucell's PER.C6 cell-line technology.
Clinical software developer, Forte Research Systems, has opened a new office in Bangalore, India, to take advantage of growth in the clinical research industry on the sub-continent.
A Lack of animal models and difficulties in proving early clinical efficacy are hampering discovery and development of psychiatric drugs according to new consortium, NEWMEDS.
Patient recruitment is boosted by health condition awareness strategies and financial incentives, according to research, but various methods of randomisation and consent design have no impact.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at Aqua Pharmaceuticals, Algeta ASA and Amarin.
Outsourcing-Pharma reviews the latest developments in drug delivery with news from HepaLife Technologies and Jeiven, SurModics and Edge, as well as EDAP, Epitarget AS and INSERM.
The European Medicines Agency (EMA) says 12-month API plant joint inspection programme has fostered greater collaboration between international drug industry regulators and cut the number of duplicate visits.
The FDA significantly increased the number of concluded post-marketing requirements and commitments (PMR/PMC) in the 2009 fiscal year, according to a report.
API maker AMRI cited arbitration costs, efforts to address a US FDA warning letter and acquisitions as key factors in Q3 loss, but predicted that large-scale contract manufacturing business will drive final quarter gains.
In the 20 month period before the heparin crisis no Chinese producers were inspected by the FDA and efforts during and since have been hindered by legal and practical challenges.
Kendle recorded a 64 per cent drop in Q3 operating income and expects its strategic review of early stage, which will establish a fair value and consider all options, to be complete next quarter.
Volunteer organisation, the Blue Bird Circle will provide grants of $1m to Texas Children’s Hospital in the US for the establishment of a new clinical research centre.
The US FDA’s Puerto Rico office may be “having difficulty” monitoring drug manufacturing in the country according to the Congressional Committee on Oversight and Government Reform.
WuXi has received GLP certification from the SFDA for its toxicology facility in Suzhou, China and, in a separate development, is providing CAS’ SciFinder to its staff.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including the departure of an FDA foreign inspections official and the search for a leader of the EMA.
Dutch biopharmaceutical company Crucell expects its operating loss for 2010 to be in the €20-25 million range, citing costs associated with microbial contamination at its Shingal facility in Korea as a key factor.
Adding Indian cGMP HPAPI capabilities builds on Arch’s strategy of differentiating through technology and establishes it in an emerging and profitable sector.
Novartis is teaming up with Arab Company for Pharmaceutical Products (Arabio) to provide Saudi Arabia and surrounding regions with vaccines for common diseases.
Celanese has launched a new controlled-release EVA excipient and says developing enhanced formulations is key to a drugmaker’s competitive edge in today’s pharmaceutical market.
Alnylam Pharmaceuticals, Medtronic and CHDI Foundation are collaborating to advance RNAi delivered by an implantable infusion device for treating Huntingdon’s.
Synteract is to hire up to 30 additional staff by the end of 2011 to work at its recently expanded site in Research Triangle Park (RTP), North Carolina, US.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at Parexel, Catalent, AMRI, BioStorage and BRANY.
RecipharmCobra Biologics has called for more R&D tax breaks in Europe after French Ministry of Higher Education and Research recognises it as key provider.
